{"transactions":[{"id":709246,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T20:32:32.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":93000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":93000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0002017800-26-000003","document":"form4-07152026_080727.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780026000003/form4-07152026_080727.xml","form_type":"4"}},{"id":851704,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:17:04.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":96899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":96899,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":96899},"source":{"system":"sec-edgar","filing":"0002017800-26-000001","document":"form4-03102026_110301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780026000001/form4-03102026_110301.xml","form_type":"4"}},{"id":968018,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:14:01.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":65676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":65676,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":65676},"source":{"system":"sec-edgar","filing":"0002017800-25-000004","document":"form4-12162025_111258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000004/form4-12162025_111258.xml","form_type":"4"}},{"id":968017,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:14:01.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":16419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":150606,"source":{"system":"sec-edgar","filing":"0002017800-25-000004","document":"form4-12162025_111258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000004/form4-12162025_111258.xml","form_type":"4"}},{"id":1018778,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:10:29.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":22435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":22435,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":22435},"source":{"system":"sec-edgar","filing":"0002017800-25-000003","document":"form4-10162025_121025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000003/form4-10162025_121025.xml","form_type":"4"}},{"id":1175878,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":2263.7451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock is convertible into 400 shares of the Issuer's common stock, subject to an issuance limitation that prohibits the holder from converting such shares of Series C Preferred Stock to the extent that, after giving effect to the issuance of shares of common stock after such conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) would beneficially own in excess of 19.99% of the shares of common stock of the Issuer then outstanding (the \"Beneficial Ownership Limitation\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of the Issuer's common stock, which was obtained on September 16, 2024, the shares of Series C Preferred are convertible into shares of common stock, subject to the Beneficial Ownership Limitation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C Preferred Stock do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":905497},"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1175877,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":605531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1294694,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:00:08.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006406","document":"tm254427-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006406/tm254427-1_4seq1.xml","form_type":"4"}},{"id":1294693,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:00:08.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006406","document":"tm254427-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006406/tm254427-1_4seq1.xml","form_type":"4"}},{"id":1375727,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":694444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":694444},"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1375726,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":539062,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":539062},"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1375725,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":1258000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":1258000,"derivative":{"exercise_price":1.3,"expiration_date":"2034-09-18","underlying":"Common Stock","underlying_shares":1258000},"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1375724,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":1443750,"price":4,"value":5775000.0,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares held directly by TPAV, LLC issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by TPAV, LLC issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2677256,"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1375723,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":694444,"price":3.6,"value":2499998.4,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":1233506,"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1375722,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2024-11-05T23:00:55.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":539062,"price":3.2,"value":1724998.4,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":539062,"source":{"system":"sec-edgar","filing":"0001213900-24-094664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017800/000121390024094664/ownership.xml","form_type":"4"}},{"id":1438999,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-07T19:46:24.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the \"Common Stock\") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-002742","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824002742/form4.xml","form_type":"4/A","original_submission_date":"2024-04-03"}},{"id":1550717,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":4801.1144,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":4801.1144,"derivative":{"underlying":"Common Stock","underlying_shares":48011144},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550716,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":2584.3663,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2584.3663,"derivative":{"underlying":"Common Stock","underlying_shares":25843663},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550715,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":194.6223,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."}],"balance_after":194.6223,"derivative":{"underlying":"Common Stock","underlying_shares":1946223},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550714,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":3802890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."}],"balance_after":3802890,"derivative":{"exercise_price":0.07,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":3802890},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550713,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":1645100,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1645100,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550712,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":885532,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":885532,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550711,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550710,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":66687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."}],"balance_after":66687,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}}]}